IDM-1

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameIDM-1

Drug Alias NameOsidemMDX-210/MAK cellsIDM-1MAK/IDM-1

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionHigh affinity immunoglobulin gamma Fc receptor I antagonistsReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2High affinity immunoglobulin gamma Fc receptor I

Therapy Area/IndicationsOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsYes MDX-210

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesTakeda Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTakeda Pharmaceutical Co Ltd

Active IndicationsN/A

Inactive IndicationsOvarian Neoplasms

Other Information

ATC CodeN/A